Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01930006 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
A Phase 1 study of Advanced Malignancies, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT01930006: Completed Phase 1 study of Advanced Malignancies, sponsored by Mirati Therapeutics.
NCT01930006 is a Phase 1 study of Advanced Malignancies that has completed, run by Mirati Therapeutics. The registered enrollment target is 14 participants, below the 88-participant average among 10 other Advanced Malignancies trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01930006, a Phase 1 study of Advanced Malignancies, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.
Primary Outcome
To compare the rate and extent of absorption of two MGCD265 oral formulations at dose level of 100 mg administered as 1 x 100 mg oral dose (Formulation A) and 2 x 50 mg oral dose (Formulation B) under fasting conditions.
Conditions Studied
Interventions
- DRUG MGCD265
Study Locations (1)
Kansas
- Vince & Associates Clinical Research, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT01930006 record still lists
NCT01930006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 88-participant average among 10 other Advanced Malignancies trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Advanced Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MGCD265 is the first listed.
NCT01930006 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01930006 about?
NCT01930006 is a clinical study titled "Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State". In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.
What is the current status of trial NCT01930006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2013-08. Estimated completion is 2013-12.
What conditions does trial NCT01930006 study?
This clinical trial studies the following conditions: Advanced Malignancies.
What interventions are being tested in trial NCT01930006?
The interventions under investigation include: MGCD265 (DRUG).
Who is sponsoring clinical trial NCT01930006?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01930006 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01930006's enrollment target sits among peer trials
14 9th of 10 higher than 1 of 10 other Advanced Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
COMPLETED · Phase 1
-
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
COMPLETED · Phase 1
-
Maintenance Study on the Long Term Safety of XL999
COMPLETED · Phase 1
-
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia